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ABSTRACT 
 
A large number of studies have applied simulation to a multitude of issues related to 
healthcare. These studies have been published over a number of unrelated publishing 
outlets, and this may hamper the widespread reference and use of such resources. In this 
paper we analyse existing research in healthcare simulation in order to categorise and 
synthesise it in a meaningful manner. Hence, the aim of this paper is to conduct a review 
of the literature pertaining to simulation research within healthcare in order to ascertain 
its current development. A review of approximately 250 high quality journal papers 
published between 1970 and 2007 on healthcare-related simulation research was 
conducted. The results present: a classification of the healthcare publications according to 
the simulation techniques they employ; the impact of published literature in healthcare 
simulation; a report on demonstration and implementation of the studies’ results; the 
sources of funding; and the software used. Healthcare planners and researchers will 
benefit from this study by having ready access to an indicative article collection of 
simulation techniques applied in healthcare problems that are clustered under meaningful 
headings. This study facilitates the understanding of the potential of different simulation 
techniques for solving diverse healthcare problems.  
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INTRODUCTION  
Healthcare needs grow and healthcare services become larger, more complex and costly 
(Wang, 2009; Eveborn et al. 2005). Moreover, the intrinsic uncertainty of healthcare 
demands and outcomes dictate that healthcare policy and management should be based 
on the evidence of its potential to tackle these stochastic problems. It seems apparent that 
computer modelling should be valuable in providing evidence and insights in coping with 
these systems. They can be used to forecast the outcome of a change in strategy or predict 
and evaluate the implications of the implementation of an alternative policy (Wierzbicki, 
2007). The use of modelling in healthcare is not limited to the management of activities 
necessary to deliver care alone. It is used for the study of several topics related to 
healthcare, for example, air pollution, pharmacokinetics and food poisoning. In this paper 
we aim at profiling studies that have designed, applied, described, analysed or evaluated 
healthcare problems with the use of simulation modelling.   
 
Computer simulation is a decision support technique that allows stakeholders to conduct 
experiments with models that represent real-world systems of interest (Pidd 2004).  It can 
be used as an alternative to “learning by doing” or empirical research (Royston 1999).  
Furthermore, simulation modelling gives stakeholders the opportunity to participate in 
model development and, hopefully, gain deeper understanding of the problems they face.  
As a result, decision-makers and stakeholders can gain a new perspective on the 
relationships between the given parameters, the level of systems’ performance, the cost-
effectiveness and its quality or risk association.  
 
In the field of Operations Management, simulation is recognised as the second most 
widely used technique after ‘Modelling’(Pannirselvam et al, 1999; Amoako-Gympah and 
Meredith, 1989). So far, there have been a number of reviews in the literature on the 
applications of simulation to health. Fone et al (2003) have conducted a systematic 
review of the use and value of computer simulation methods in population health and 
healthcare. Eltabi et al (2007) reviewed the application of a diverse range of simulation 
techniques in healthcare settings.  Brennan et al (2000) and Barrios et al (2008) 
considered the application of simulation in the economic evaluation of health 
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technologies and health products as well as a proposed method for the evaluation of 
pharmacoecomonic models (Hay, 2004). Dexter (1999) includes a review of computer 
simulation and patient appointment systems. A number of reviews have focused on the 
applications of Discrete-Event simulation in healthcare in general (England and Roberts, 
1978), and more specifically in health clinics (Jun et al, 1999) and healthcare capacity 
management (Smith-Daniels et al, 1988). Hollocks (2006) gives a personal review of the 
use of Discrete-Event simulation in health among other fields. 
 
However, most reviews limit themselves to either a single application area or/and a single 
simulation technique. Most of the current reviews lack the breadth of simulation 
techniques, the width of applications coverage and are published in outlets of different 
fields (e.g. medical, OR, health informatics journals, etc.), thus potentially hampering the 
widespread reference and use of such  studies.  
 
Hence, the purpose of this review is to fill these gaps and categorise and synthesize 
academic literature pertaining to the use of computer simulation in health problems a) 
over a number of unrelated publishing outlets, b) with a broader scope of simulation 
techniques and c) in a variety of health applications. This would, in turn, help in 
ascertaining the current development in the field of healthcare simulation.  
 
In light of the above, by sampling publications pertaining to the application of simulation 
in the healthcare domain we hope to realise the following objectives: (1) to classify 
publications according to the simulation methods they employ; (2) to determine the 
healthcare problems often investigated by these methods and to analyse their trends; (3) 
to identify the impact of published simulation research in the healthcare context; (4) to 
monitor results’ demonstration and implementation; (5) to identify funding sources for 
healthcare simulation studies; (6) to identify software associated with the studies and 
show their frequency of use. In order to achieve these objectives we have conducted a 
review of 251 articles published during the period 1970-2007. The main objective of this 
review is to offer a broad and extensive picture of the role of simulation techniques in 
health. To the best of our knowledge objectives (1) and (2) have not been previously 
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investigated in a single study for all four selected simulation techniques in the health 
sector, and objectives (3) to (6) have not been presented in a published source - with the 
exception of England and Roberts (1978) who presented similar results for Discrete-
Event simulation and System Dynamics over 30 years ago. It is hoped that the findings of 
our analysis will be beneficial to the community of simulation and health-related 
academics and practitioners.  
 
The remainder of this paper is structured as follows. The next section (‘Simulation 
Modelling’) provides a discussion of the different simulation methods selected for this 
study. The methodology employed for the research is explained under the ‘Research 
Methodology’ section. The section on ‘Research Paradigm’ categorises the applications 
of simulation under various simulation techniques and healthcare problems – this fulfils 
objectives (1) and (2). This is followed by the ‘Research Impact’ section (fulfils objective 
3) that identifies some important papers that have been reviewed in our study and 
measures their impact through a citation-based analysis.  The section on ‘Results 
Implementation, Funding Sources and Analysis of Simulation Software’ presents 
statistics pertaining to these variables, and thereby fulfils objectives (4), (5) and (6). The 
penultimate section presents a ‘Discussion’ of the findings of this study and the paper 
concludes with ‘Conclusions and Further Reflections’ that outlines the limitations of our 
approach and reflect on the contribution of this work. 
 
SIMULATION MODELLING 
The simulation modelling techniques that were found appropriate for the purposes of this 
study are Monte Carlo Simulation (MCS), Discrete-Event Simulation (DES), System 
Dynamics (SD) and Agent-Based Simulation (ABS). Journal papers included in this 
study have been selected based on the criteria that the papers report on the use of one or 
more of these simulation techniques in the healthcare settings.  The choice of simulation 
techniques was made through interaction with experts in this area but was also backed by 
the review of Jahangirian et al (2009) of simulation in business and manufacturing. The 
latter identifies the following simulation techniques: DES, SD, ABS, MCS, Intelligent 
Simulation, Traffic Simulation, Distributed Simulation, Simulation Gaming, Petri-Nets 
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and Virtual Simulation, excluding simulation for physical design. According to this study 
the first five techniques were the most commonly presented/used in the selected papers 
for that review. Initially in our study we also considered papers that reported on the use of 
Intelligent Simulation and Parallel & Distributed Simulation (PADS). However, these 
categories were later dropped owing to the fact that only a few relevant papers pertaining 
to the aforementioned categories were found in our sample study (one or two for each 
category). Moreover, our choice of simulation techniques is further supported by the 
study conducted by Fone et al (2003), wherein DES, SD and MCS are discussed as 
popular simulation techniques in healthcare. Those who wish an introduction to the 
aforementioned techniques can refer to Rubinstein (1981) for MCS, Robinson (1994) for 
DES and Sterman (2001) for SD. ABS is the most recent of the four simulation methods 
used since the mid-1990s. A brief description of ABS is provided below. 
 
ABS is a computational technique for modelling the actions and interactions of 
autonomous individuals (agents) in a network. The objective here is to assess the effects 
of these agents on the system as a whole (and “not to” assess the effect of individual 
agents on the system). ABS is particularly appealing for modelling scenarios where the 
consequences on the collective level are not obvious even when the assumptions on the 
individual level are very simple. This is so because ABS has the capability of generating 
complex properties emerging from the network of interactions among the agents although 
the in-built rules of the individual agents’ behaviour are quite simple.  
 
RESEARCH METHODOLOGY 
In this paper we have conducted a review of literature in healthcare simulation. Our 
review method has been influenced by the systematic literature review approach adopted 
by Eddama and Coast (2008), wherein (a) databases such as ISI Web of Science® and 
MedLine® were searched using a combination of search terms, (b) papers were screened 
by reading article titles and abstracts and in accordance to some inclusion criteria, and (c) 
the contents of the papers selected in the earlier stage were reviewed. Our literature 
profiling methodology consists of two stages and is illustrated in Figure 1. Stage 1 is the 
“Paper Selection” stage and it describes the methodology used for the purpose of 
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selecting papers for inclusion in this study. Stage 2 is the “Information Capturing” stage 
and it identifies the information that is captured from papers that have been included in 
the study; the latter is analysed in the subsequent sections of this paper (sections 4, 5 and 
6). Both the stages of our methodology are further described below. 
 
Figure 1 about here 
 
The papers selected for this study were identified from the Web of Science® database. 
The Web of Science® is one of the largest databases of quality academic journals and 
provides access to bibliographic information pertaining to research articles published 
from 1970 onwards. It indexes approximately 8,500 high impact research journals, from 
all around the world, spread across approximately 200 different disciplines. Our aim was 
to identify publications with the highest credibility and thus we looked only at journal 
articles having an impact factor (note: only journals with an impact factor are included in 
the ISI Web of Science® database).We do recognise, however, that other bibliographic 
databases could have also been looked at. But for the purpose of this research, we decided 
to include only the Web of Science® database since this study is not a systematic review 
but it is a sample review of publications in healthcare simulation. 
 
The Web of Science® has a user friendly search engine that assists in the refinement of a 
search by allowing the user to incorporate specific search conditions. Our search strategy 
was driven by the simulation methodology used in the sought after papers. To identify 
articles which would be incorporated in our study’s dataset the following criteria were 
used: inclusion of the words, “simulat*” OR “health*” in the article’s title and both of 
the words/phrases (“Monte SAME Carlo” AND “health*”) OR (“Discrete SAME Event 
*” AND “health*”) OR (“System* SAME Dynamics” AND “health*”) OR (“Agent 
SAME Based” AND “health*”)  in the abstract or keywords of the published paper. The 
SAME operator returns records where the terms separated by the operator appear in the 
same sentence. The use of the asterisk “*” in the Boolean keywords combination, allowed 
for the inclusion of keyword derivatives in the search options. The search identified only 
articles and review papers written in the English language from 1970 until 2007 
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(inclusive). Results from this initial search strategy are shown in the 2nd and 3rd columns 
of Table I. Sampling returned 251 papers in total.  
 
The second step involved the screening of these papers. The two authors independently 
and critically reviewed all 251 papers’ abstract and read the full-text when necessary. The 
appraisal was carried out based on certain inclusion criteria as follows: The selected 
papers should evidently demonstrate strong relation with the healthcare sector or have an 
impact on healthcare and use the chosen simulation method to describe, analyse or assess 
the situation. The paper should spend at least one paragraph describing the applied 
simulation method that was used in the study. Thus, pure physics simulations and human 
systems simulations did not fulfil the inclusion criteria. The boundaries between health-
related papers and non health-related papers were not always straightforward. In many 
papers the impact on human healthcare is provided by a less direct relationship. The 
reviewers took a flexible approach by including papers which one could clearly relate the 
problem described with some kind of health impact. Each of the reviewers assessed all 
abstracts independently and results were compared. In cases of discrepancies, the full-text 
of the paper was examined and after discussion between the reviewers a decision was 
reached for the paper’s inclusion or exclusion. This filtering resulted in a set of 201 
relevant papers.  The full-text papers were collected via online or inter-library loan 
services. 
 
The second stage concentrated on the content of the 201 papers in order to answer the six 
objectives of our study as identified in the introductory section. Of the selected papers, 
MCS seems to be by far (69%) the most applied method dealing with health issues. It is 
followed by DES and SD. Finally, the method with the least number of papers is ABS - 
this is not a surprise since it is the most recently developed simulation technique. Table I 
(last 2 columns) lists the results of our screening. The last row of the table (“multiple 
simulation methods”) identifies five papers which use or mention two or more simulation 
techniques. These (“multiple simulation methods”) papers for simplicity purposes are 
described under the research paradigms of the four identified categories as explained in 
the next section. As this is a sample review, no inferences can be drawn from Table 1 as 
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to the impact of each simulation method in healthcare. Nonetheless, we believe that the 
statistics below provide the readers with some understanding of research trends in this 
area.  
 
Table I about here 
 
RESEARCH PARADIGMS 
The papers that have been included in our review are listed in separate tables [Table III – 
Table VI]. These tables are presented in the relevant sub-sections associated with each 
simulation technique in question. Every paper has a unique identifier beginning with the 
initials of the simulation method under which it is categorised (MC, DES, SD, ABS) and 
is suffixed with a numerical value, example, MC1, MC20, etc. When many papers are 
listed in a row under the same category then the prefix is entered only at the beginning 
and is omitted from the rest of the papers for brevity e.g. [MC11, 27, 81]. In the tables 
these papers are presented in a descending date of publication order, and this, in turn, 
shows the research effort over these 37 years. Thus, small numbers correspond to the 
most recent publications and large numbers to the older ones. The Vancouver reference 
style is followed. Rather than including the references alphabetically at the end of the 
paper, we consider this scheme of collecting and tabulating all references pertaining to a 
particular simulation technique together at the end of each section as important because 
we feel that it improves the readability of the paper. These tables will also serve as a 
future reference/study-list for the reader. 
 
The papers pertaining to the different simulation techniques have been categorised under 
several general headings/categories. An overview of these categories is presented in 
Table II (objective 1). This is followed by a discussion of the categories under each of the 
four identified simulation techniques (objective 2). Some papers can be categorised under 
multiple headings and the decision to favour one classification category over the other 
was based on the relative importance attributed to specific simulation technique in the 
discussion part of the paper. 
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Table II about here 
 
Monte Carlo Simulation (MCS) 
MCS is the simulation technique most predominantly used out of the four identified 
techniques. Of the 163 reviewed papers in MCS we found 142 to be suitable for inclusion 
in our dataset.  
 
In the context of healthcare, MCS has generally been used for the following purposes: (a) 
to assess health risks from exposure in certain elements and determine drug dose-
response portions. This is the most popular sub-category with 60 papers in our sample. 
(b) As the main approach to modelling used in economic evaluations in healthcare 
interventions when there is a need to increase the number of states in the model to 
overcome the homogeneity assumptions inherent in Markov models and decision trees 
[Barton et al . 2004] (18 papers). (c) To evaluate the cost-effectiveness of competing 
technologies or healthcare strategies that require the description of patient pathways over 
extended time horizons with 41 papers in this sub-category. (d) Miscellaneous 
taxonomies, literature review and feasibility studies with 23 paper altogether. Each of 
these four issues will now be looked at in greater depth.  
 
 Health Risk Assessment  
Numerous environmental and occupational studies have shown a link between measures 
of public health and the intake of contaminants, via different environmental media and 
exposure routes such as inhalation, skin and ingestion. Twenty-two studies focused on air 
pollution [MC 3, 10, 20, 26, 29, 40, 43, 51, 55, 79, 88, 90, 97, 102, 114, 124, 126, 132, 
133, 135, 136, 140], 9 on water pollution [MC 21, 62, 76, 93, 95, 98, 103, 116, 127], 11 
on food poisoning [MC 5, 13, 34, 56, 77, 100, 111, 113, 118, 122, 125] and 3 on soil 
contamination [MC 119, 128, 142]. In such health risk assessments or epidemiology 
studies the exact amount of a chemical or contaminant that an individual comes into 
contact with over a lifetime should ideally be estimated. However, for many obvious 
reasons this estimation is difficult. Simulation studies can fill in data gaps regarding 
historical exposures by generating these data using parametric functions which are critical 
to improving the power of such studies. MCS is the method most commonly used for 
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classical probabilistic risk assessments and uses mathematical or statistical models to 
estimate the frequency in which an event will occur.  This technique is particularly useful 
when a large number of algorithms are required to address various multi-pathways of 
exposure to humans. The use of Monte Carlo analysis has reformed the practice of 
exposure assessment and has greatly enhanced the quality of the risk characterization. 
 
Moreover, 15 risk assessment studies focus on drug development and dose-response 
portion [MC 4, 14, 17, 19, 31, 42, 47, 52, 53, 54, 67, 71, 80, 106, 137]. MCS can be used 
to determine the Probability of Target Attainment (PTA) of pharmacodynamic indices by 
taking the inherent variation of different populations into account. In MCS, the model 
parameters are treated as stochastic or random variables e.g. by use of a probability 
density function, rather than fixed values. The aim of these studies is to establish a 
population pharmacokinetic model to study the parameters for the drug being 
administered through an intravenous escalating dosing regimen in healthy subjects, which 
could, inturn, be used for design of patient protocols with direct therapeutic benefit and 
maximal safety. These simulations are dependent on the assumptions in the model, 
including the types and number of subjects in the pharmacokinetic studies and the data 
used. Differences in pharmacokinetic parameters (for different patient populations) 
and/or data can lead to differences in the target attainment rates obtained with these 
simulations. Studies of these kinds usually derive their data from clinical trials.  
 
 Prognostic and Transmission Models of Health Interventions.  
MCS is extensively used to measure the number and impact of medical interventions for 
the prevention of disease deterioration or disease transmission. Many intervention 
procedures with medical treatment show substantial reductions in disease morbidity or 
mortality. However, their use is expensive and to some extent determined by local 
practice, with great variation in the rates of these procedures. The optimum level of such 
procedures may therefore be uncertain, and this uncertainty is a major problem for both 
clinicians and health service administrators. It is therefore important to have methods that 
model the requirements for these interventions at the population level by capturing the 
movement of individuals between different states based on disease and/or procedure 
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history. Such interventions that usually involve patients or disease transmission stages 
use Markov processes to measure the probabilities of transmission. MCS analysis of the 
Markov process is the most useful model for this situation which also allows the 
enumeration of events as individuals move between states [MC1, 2, 22, 32, 39, 48, 57, 
58, 59, 64, 66, 75, 84, 91, 94, 99]. Moreover there are studies which seek to develop 
criteria that classify risk factor levels during intervention or treatment outcomes after 
intervention. In such studies regression-analysis is the most commonly used tool (some 
others are Bayesian statistics and bootstrapping) that specifies the inclusion criteria or 
variables. MCS is used in addition to this method to investigate the robustness of these 
variables or classification criteria [MC49, 74]. Subsequently, in these studies MCS 
techniques evaluate the propagation of the variability of input parameters used in 
regression models by analyzing the effects of uncertainty and intrinsic variability of 
parameters. 
 
 Cost-benefit Analysis and Policy Evaluation of Medical Treatment and Disease 
Management Programs 
The above research can easily be adapted or expanded to fit economic data which 
evaluate the cost-effectiveness of specific interventions, treatments, tests and health 
programs. Certain medical conditions have a profound and growing impact on healthcare 
resource utilization. In many circumstances the direct expenditures for screening or 
treatment (with drugs or other therapy) of these conditions have substantially increased 
due to the overall ageing of the population. Therefore, research in this field tries to assess 
the economic value of a population-based screen-and-treat strategy for diseases or 
medical conditions compared to alternative strategies or no intervention [MC 6, 7, 9, 12, 
16, 23, 25, 35, 37, 38, 39, 40, 44, 45, 46, 50, 60, 63, 65, 68, 70, 72, 73, 82, 83, 87, 89, 92, 
96, 101, 108, 109, 112, 117, 120, 131, 138, 139]. Briefly, a Markov state transition model 
with different health states is developed to simulate the medical condition fractures or 
disease states as a function of demographic change and other influences allowing for a 
wide variety of scenarios regarding planned medication usage, drug efficacy, and 
individual persistence with treatment. The cost-effectiveness of these alternative 
strategies is evaluated in a MCS-based incremental cost-utility analysis. The main 
12 
 
outcome is usually cost per quality-adjusted life year (QALY) gained. These results 
provide policy makers with a common metric for comparing diverse technologies and 
programs. Model inputs for the simulation models are usually obtained from published 
literature and surveys, expert interviews and clinical trials and studies.   
 
 Miscellaneous 
There are a number of MCS studies emerging from our search strategy that form smaller 
categories or do not clearly fall within a distinguished category. These studies are 
literature review studies and taxonomies of various statistical methods, including Monte 
Carlo simulation, that can be useful decision tools pertaining to a particular health 
problem and usually pertinent to risk assessment [MC11, 27, 81]. Other studies focus on 
the development of new methods, for example, probabilistic public health risk 
assessment/treatments or improvement of an existing modelling method or comparison 
between different methods in the form of feasibility studies [MC 8, 18, 30, 36, 60, 69, 78, 
86, 105, 110, 115, 121, 123, 129, 130, 141, 142] (16 papers). Finally, there are MCS 
studies about health surveys and service delivery examination, including for example, the 
determinants of health and measures of health status, the quality of hospital care, and the 
impact of demographic change on the need for hospital resources [MC23, 104, 107, 134]. 
 
 Table III about here 
 
Discrete-Event Simulation (DES) 
This is the second most popular category in our study with 40 papers overall after 
screening. It is said that DES can create significantly more insight than MCS in areas 
such as health economics (Eldabi et al., 2000). Applications of DES in health have been 
clustered under the following headings: (a) Planning of healthcare services described in 
13 papers in our search. (b) Health economic models which are presented in 10 papers (c) 
7 review and 6 methodology papers, and (d) contagious disease interventions presented in 
4 papers.  
 
An extensive taxonomy of DES studies in healthcare over the past twenty years is 
presented in Jun et al. (1999) and Fone et al. (2003).  The study conducted by Fone et al. 
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(2003) is a systematic review from 1980 to 1999. Our DES categories bring some 
similarities to these identified by Fone et al (costs of illness and economic evaluation, 
hospital scheduling and organization, infection and communicable disease, screening and 
miscellaneous). The work done by Jun et al. (1999) is a survey specifically on the 
applications of DES to healthcare clinics over the 80’s and up to 1997. The categories 
identified by Jun et al (patient scheduling and admissions, patient flow schemes, and staff 
scheduling on patient flow and work flow, allocation of resources when sizing and 
planning beds, rooms, and staff personnel) also bear resemblance to our sub-categories in 
‘Planning Healthcare Services’ as the latter study is focused on a specific area of DES 
and is more analytic. We now discuss each of our DES categories according to the 
number of publications identified in each cluster in a descending order. 
 
 Planning of Healthcare Services and Health Interventions 
DES allows decision makers to effectively assess the efficiency of existing healthcare 
delivery systems such as hospitals [DES29], to improve system performance or design, 
and to plan new ones in a risk-free and costless environment by investigating the complex 
relationships among the different model variables (i.e. rate of arrivals, time spent in the 
system, etc.) and overcoming bottlenecks. The scope of evaluation can be micro in scale, 
for example by examining resource needs in terms of scheduling staff and measuring bed 
and equipment capacity at individual clinics, or macro in proportion (healthcare policy 
for the entire population). DES allows the decision makers to gather insights and obtain 
approximate results of the differing but competing policies that may be implemented in 
the future. Moreover, since DES allows the creation of dynamic population-based 
models, wherein each entity in the simulation represents an individual, the results could 
indicate the number of people who may be affected by adoption of a particular strategy.  
 
Some of the applications of DES therefore relate to managing patient admissions and 
staff scheduling, for example DES studies that compared the “individual surgeons” 
strategy with the “pooled lists” strategy for scheduling outpatient clinical appointments in 
surgical care [DES6]; designed a new house staff work schedule [DES35] and ambulance 
schedules [DES24]. They also relate to identifying areas of improvement of service 
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through possible reorganization of existing resources, for example: reorganization of 
surgical and anesthesia care surrounding laparoscopic surgery [DES21]; experimenting 
with real-time health information system to reduce response time [DES40]; evaluating 
operating policies in clinical environments [DES28] and allocation policies for liver 
transplantation [DES17]; forecasting the impact of changing demand for treatment of 
irreversible renal failure [DES33] and planning for the geographical locations of new 
healthcare services taking into account the demographics of the population and the 
location of the patients who need the services [DES18]. Furthermore, DES is well-suited 
to tackle problems in A&E departments, where resources are scarce and patients arrive at 
irregular times [DES2], and can effectively combine Total Quality Management 
strategies [DES24] and data mining [DES8] for better results. Moreover, DES 
applications relate to estimating performance measures impacting facilities design and 
planning of veterinary practice [DES37]. As large majorities of the population depend on 
edible products or by-products from livestock, the health of livestock has a significant 
effect on public health.  
 
 Health Economic Models 
Health economic models evaluate the health implications and the economic costs of 
providing healthcare to the population at large. They usually do so by comparing 
alternative healthcare interventions, aiming to maximize welfare through optimal 
utilization of the allocated public health funds.  With respect to health economic models, 
the use of DES has been reported for evaluating, among others, the cost of providing 
dental care to children [DES1]; for comparing methods of managing chronic 
osteoarthritis pain [DES3];  for modelling the treated course of schizophrenia so as to 
estimate the long-term costs and effects of new interventions [DES15]; for evaluating the 
cost effectiveness of screening strategies for diabetic retinopathy by varying the screening 
method and interval [DES27,36] and of introducing a range of automated image analysis 
systems for cervical screening programs [DES16]; for estimating the cost-effectiveness 
and the direct healthcare costs pertaining to insulin-dependent diabetes mellitus [DES34]. 
The use of DES health economic models have also been reported for the economic 
evaluation of pacemakers. For example, DES was used for modelling the health benefits 
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and economic implications of implanting dual-chamber vs. single-chamber ventricular 
pacemakers in the UK [DES14] and of implanting a Cardiac Resynchronization device 
(DESacemaker) of Therapy (CRT) for reducing heart failure as opposed to Optimum 
Pharmacologic Therapy (OPT) that does not require a pacemaker [DES13]. DES was also 
used to improve the National Blood Service (NBS) supply chain by investigating 
different blood ordering and distribution policies [DES7].  
 
 Review and Methodology papers 
Our research methodology identified a number of review papers in the healthcare 
literature. Some of these papers compared modelling techniques used in healthcare, such 
as DES, Markov and semi-Markov chain models, queuing models and deterministic 
models (in the context of patient flow models [DES39] and economic evaluations of 
health-care technologies [DES22]) and presented taxonomies of modelling structures 
[DES5, 10, 32]. Other papers present a personal reflection of DES [DES12] and outline a 
vision of the future use of simulation in healthcare [DES9]. They all found DES to be 
particularly suitable for estimating cost and health benefits of dynamic population-based 
models with individual attributes and patient care systems with scarce resources.  
 
In our search, five methodology papers were identified. They deal with various issues 
such as: the use of patient-chart-driven computer simulation to advance A&E system 
[DES20]; the use of DES as one emerging modelling technique for supporting decision 
making in a randomized clinical trials of breast cancer [DES31]; for modelling patient 
behaviour when screening for diabetic retinopathy [DES25] and for evaluating imaging 
technologies [DES4].  Moreover, DES has been acknowledged as a well suited 
methodology for modelling health systems [DES38] and a valuable training tool for 
students who learnt to analyze and design efficiently workflow processes in healthcare 
[DES30].  
 
 Contagious Disease Interventions  
DES applications in this category usually relate to proposing ways to suppress the spread 
of HIV in developing countries [DES19, 23] and to the public response to control the 
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outbreak of contagious diseases that may be caused by natural occurrence [DES11] or an 
act of terrorism [DES26]. These DES models are developed to plan emergency clinics 
and distribution centres for mass-dispensing and vaccination. 
 
Table IV about here 
 
System Dynamics (SD)  
SD can assist the design of healthcare policies by examining how the fundamental 
structure might influence the progressive behaviour of a system. It takes into 
consideration factors such as the time variation of both the tangible elements, such as 
waiting times and healthcare costs, as well as intangible elements, such as patient anxiety 
and the effects of various pressures on purchasing decisions (Taylor and Lane, 1998).   
Seventeen studies are counted under this technique. The papers pertaining to SD 
have been categorised under the following headings: (a) Public health policy evaluation 
and economic models, represented in 9 papers in our search. (b) Modelling healthcare 
systems and infrastructure disruption (4 papers). (c) Use of SD as a training tool (3 
papers) and (d) 1 review paper of SD for modelling public health matters of disease 
epidemiology and healthcare capacity [SD6].  The first three categories are described 
below in the same order as above. The papers are listed in Table V. 
 
 Public Health Policy Evaluation and Economic Models 
SD has been applied for the evaluation of several public health policies. With regards to 
communicable diseases, SD models were developed to estimate the effect of harm 
reduction policies for HIV/AIDS and tuberculosis (such as “needle-sharing and injection-
frequency among drug users and multi-drug resistant tuberculosis control [SD2]) and to 
assess economic consequences of testing and treating pregnant women for HIV virus with 
different regimens to avoid prenatal transmission [SD16]. Moreover, SD was used in 
several studies to evaluate the long-term health impact of smoking by comparing policies 
such as increasing cigarette excise taxes, raising the legal smoking age to 21 [SD4] and 
introducing tobacco harm reduction policies [SD8, 9, 11]. They suggested that a large tax 
increase would have the largest and most immediate effect on smoking prevalence. 
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Control over the cigarette content would bring a net gain in population health although 
“healthier” cigarettes make smoking more attractive and increase tobacco consumption. 
SD has also been used by health planners to: gain a better understanding of diabetes 
population dynamics [SD7]; to model the feedback effects of reconfiguring health 
services [SD10] by shifting towards the primary level and bringing services ‘closer to 
home’; to investigate the impact of privacy legislation in the individual health insurance 
market and the social costs that are borne when applicants do not divulge private 
information about their medical conditions [SD14]. 
 
 Modelling Healthcare Systems and Infrastructure Disruptions 
A healthcare system consists of many individual sub-parts that interact with each other, 
for example the national health system (NHS) consists of vast numbers of GP clinics, 
walk-in centres, hospitals, tertiary care centres, A&E, IT infrastructure, NHS supply 
chains, etc. SD allows modelling of several sub-parts of these complex healthcare 
systems, such as a city’s delivery of emergency and on-demand, unscheduled care 
[SD12], an A&E dynamics of demand pattern, resource deployment and parallel hospital 
processes [SD15]. In this regard, SD also has the potential to simulate multiple, 
independent key elements of an infrastructure. Innovative modelling and analysis 
framework based on SD could study the entire system of physical and economic 
infrastructures and specifically of healthcare facilities and propose public responses to 
infrastructure disruptions [SD5] and disasters [SD1], as well as to reduce the devastating 
health effects of such phenomena by modelling into a unified whole the relief effort of 
evacuations, provision of temporary shelters, restoration of electricity and communication 
lines, etc.  
 
 Training 
SD has also been used as a tool for training health policy makers. SD can facilitate the 
understanding of the dynamics of an epidemic such as SARS [SD3] and explore 
applicable combinations of prevention or suppression strategies. Moreover, SD provides 
an opportunity in some educational environments such as in health sciences by allowing 
students to experiment in the classroom with the use of professional tools. SD software 
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together with calculator-simulators has been used for teaching pharmacokinetics [SD13] 
and pharmacological system dynamics models have also been developed for the same 
purpose [SD17].  
 
Table V about here 
 
Agent-Based Simulation (ABS) 
Applications of ABS in the healthcare sector are not yet widespread but it has been used 
to study problems such as the spread of epidemics (Bagni et al, 2002).  The research 
methodology that we have followed in our review has identified only two papers that 
have used ABS. The papers are listed in Table VI below.  
 
One study reported an ABS model called CancerSIM which allows researchers to study 
the dynamics and interactions of cancer hallmarks and possible therapies [ABS1]. The 
other study [ABS2] used software agents to preserve individual health data 
confidentiality in micro-scale geographical analyses and showed that by limiting the 
accuracy of geocodes for the purposes of privacy protection, the ability to identify areas 
of high disease risk is degraded. 
 
The five papers which report on several simulation techniques (refer to Table I) have 
been included in the MCS and the DES category for the sake of simplicity.  Three papers 
report both on MCS and DES and were described under the “Prognostic and transmission 
models of health interventions” [MC48, 58] and the “Cost-benefit analysis and policy 
evaluation of medical treatment and disease management programs” [MC65] headings of 
MCS. Moreover, there are two papers which were described under the “Review papers” 
heading of DES. A review paper [DES9] which refers simultaneously to DES, SD and 
MCS and a taxonomy paper [DES10] which refers to DES and SD among other 
operational research techniques. 
 
Table VI about here 
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RESEARCH IMPACT 
In this section we present the citation statistics of a few highly-cited papers in the field of 
healthcare simulation (objective 3). The table shows the total citations and the average 
article citations as a means of identifying the impact of these publications. The list is 
sorted (and therefore publications for inclusion in Table VII are selected) based on the 
total citation count. However, the authors recognise that the average citation is also a very 
useful measure as it eliminates the discrepancies caused by the number of years passed 
since publication. It is generally expected that review papers have more citations than 
research papers. It is therefore surprising that none of the papers included in the list 
below are review papers. Even more surprising is the fact that all papers use the MCS 
technique as their main method of analysis. Many of the papers in table VII present cost-
effectiveness analyses of specific healthcare applications or disease prevention methods, 
including the first paper which was published in the journal Bone in 1994.  
 
Table VII about here 
 
It should be noted here that a good number of journals in Table VII are either medical or 
health related journals. It is widely accepted that medical journals generally have citations 
that are much higher compared to the OR journals that it might be concluded that impact 
is incomparable between them. A more stratified representation would shed more light. 
However, this was out of the main scope of this study.   
 
RESULTS IMPLEMENTATION, FUNDING SOURCES AND 
ANALYSIS OF SIMULATION SOFTWARE  
In this section we examine the evidence of results presentation, implementation 
(objective 4), funding (objective 5) and software usage (objective 6) from amongst those 
papers that were selected for inclusion in this study after screening. 
 
Of the 201 papers, 184 (91%) present results and have a separate, typically large section 
supported with tables and graphs to give a full analysis and explanation to the readers. 
There are 7 MCS papers, 8 DES, 3 SDS and 1 ABS paper that do not present results. Of 
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these, the majority are review and methodology papers. There are only 5 papers which 
fall in other categories (health risk assessment; health economic model; planning of 
healthcare services) and do not demonstrate results in a numerical format in the way 
described above. Yet, implementation of research results is hardly mentioned in these 
publications, with only a few papers (11 out of 201, 5.4%) reporting on the 
implementation of results to the stakeholder organisations in which the case studies were 
based. Six are reported in the MCS category, 4 in DES and 1 in SD. However, this is not 
to say that the case oriented simulation studies that have not implemented their results 
have gone astray. Nor should it be implied that their impact is only academic and does 
not reflect the real world. Looking further at the issue one may realise that healthcare 
simulation studies generally have a long gestation period before they reach the ultimate 
decision makers in a comprehensive format. These decision makers need to decide among 
a plethora of similar studies, taking into consideration various other factors, and come to 
a conclusion of turning a specific recommendation from a study into a policy applicable 
in health organisations and settings. Subsequently, it is unlikely that implementation will 
be part of the paper. Moreover, researchers are eager to publish once they have the first 
results in hand and only very occasionally will they wait until the impact of their method 
is shown in the real world in order to incorporate it into their paper.  
 
Perhaps a better measure of the interest in the research being conducted in the healthcare 
simulation studies is the funding process. Of the 201 studies, 87 (43%) have received full 
or partial funding. Of the 163 identified MCS studies around 39% mention their project’s 
funding source; 48% of the DES papers, 65% of the SD papers and 100% of the ABS 
papers (2 papers) report a funding source. Many of these papers refer to various sources 
of funding. Table VIII below illustrates some of these sources. As can be seen from the 
table, health departments and national foundations are the major sources of funding, 
closely followed by pharmaceutical companies. Other governmental departments and 
national institutions also fund healthcare studies. Funds for research are also derived from 
internal University funding and research council grants. 
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From our sampled list of papers we find that funding seems to be consistent throughout 
the years. This suggests that there is no identified trend that more funding is provided for 
healthcare research over the last years or vice versa.  
 
Table VIII about here 
 
Finally, we conclude by presenting some statistics on simulation software/programming 
languages that were used to support model development in the selected studies. It is 
important to mention that, from our sample of 201 selected papers, only 83 papers 
acknowledge the software or programming language that was used to develop the model. 
This data is presented in Table IX (MCS software), Table X (DES software) and Table 
XI (SD software) respectively. With regards to MCS (Table IX), @Risk and CrystalBall 
were amongst the most popular software, followed by Excel. Numerous other software 
and programs have also been used, some of them specific to health or other applications. 
 
Table VI about here 
 
The process of building DES models involves some form of software. The software can 
either be a high-level programming language or a Commercial, Off-The-Shelf (COTS) 
simulation package. DES software Arena is the most popular in this sample review, 
followed by the programming language Borland Delphi and COTS package Simul8 
(Table X). 
 
Table X about here 
 
As for SD, the use of only few types of software is reported. Vensim is first in the list, 
closely followed by Stella. Dynamo comes last (Table XI).  
 
Table VI about here 
 
Finally, one of the two ABS papers reported the use of the programming language C++ to 
create CancerSIM.  
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In general, the rapid growth in simulation software technology has created numerous new 
application opportunities, including more sophisticated implementations, as well as 
combining simulation and other methods for complex models and processes. Trends from 
our data analysis suggest that in the most recent years COTS packages have taken the 
lead over one-off models that are coded using programming languages. This is explained 
by the fact that COTS simulation packages are rapidly evolving through inclusion of 
more advanced features (e.g., 3-D graphics, parallel processor support, etc.). 
 
DISCUSSION  
The field of healthcare simulation has evolved significantly over the past 30 years. A 
great number of health problems have been approached with simulation techniques which 
have offered greater precision with regards to resource allocations, evaluations between 
health strategies and risk assessments. In this review paper reflecting on 37 years of 
healthcare simulation, we see some trends that apply to the discipline as a whole.  
 
Looking first at the statistics of our sampled papers, we could derive the conclusion that 
the proportion of papers published in the field has drastically increased, with more than 
three-quarters published after 2000. Annual paper contributions amounted from 1 paper 
in 1988 to 36 in 2007. It is, however, surprising that the oldest paper in our dataset is 
from 1988 since our search strategy concentrated on identifying healthcare simulation 
papers published from 1970 onwards. One reason for this is possibly that the number of 
journals indexed by ISI WoS has swelled with the rising popularity of the Internet and the 
availability of electronic bibliographical information (this may not have been the case 
during 1970s-1980s). Furthermore, it is arguable that although simulation has been 
applied to manufacturing, defence, supply chains etc., for a long time, its application in 
the healthcare context is comparatively new. Figure 2 illustrates the historical trends of 
healthcare modelling papers for each simulation technique (the only exception is ABS 
which has only two papers). The ascending lines show the increasing number of 
published papers in the field especially after the mid 1990’s for all three simulation 
methods. This is in line with the clear increase in simulation usage in the general service 
sector during the 1990s onwards (Robinson, 2005). Year-to-date figures suggest that this 
23 
 
gradual upward trend will continue. It is apparent that during the last four years the 
published papers in this field have drastically increased. A reason might be the possible 
increase of funding in recent years (Murphy and Topel, 2003).  
 
Figure 2 about here 
 
Simulation as a technique in health problems is used both as the main methodology of the 
research and as a supportive method to evaluate the robustness of other methods in 
different papers. MCS seems to be the most popular simulation technique in health 
studies and the majority of papers fall within the health risk assessment category. In this 
category studies pertaining to air and water pollution, food poisoning and soil 
contamination are leading in terms of published papers and drug development and dose-
response portion studies follow. Cost-benefit analyses health studies with the use of MCS 
are also popular. They assess the economic value of population-based screen-and-treat 
alternative strategies for diseases and medical conditions. Some of these studies hold the 
first positions in terms of research impact as found to have the maximum average number 
of citations in our dataset. Moreover, it is particularly noticeable that of the 142 MCS 
papers, none were published in an OR journal (as defined by the Association of Business 
School-ABS list). One reason for this may be that MCS is extensively used by health 
professionals/academics who wish to publish in health related outlets or that OR 
academics have lost interest in the use of MCS and have focused in the use of other 
simulation techniques to tackle health problems. Nevertheless, several of the MCS papers 
identified in our study would fit the aim and scope of OR journals. For example MC 7, 8, 
9, 23, 25, 26, 2, 30, 32, 38 and many more. 
 
In the analysis of the research paradigms categories, it is obvious that some overlap exists 
among the health applications examined by simulation technique. A very apparent 
example is that all simulation techniques deal with screening strategies and cost-benefit 
analysis of medical interventions. Assuming that the categorisation of papers was made 
according to the health problem tackled and regardless of the simulation technique 
employed, the papers of cost-benefit analysis would be at about the same level of the 
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health risk assessment category. However, many researchers will agree that although the 
application area is the same, the extent, the level and the detail at which this is examined 
differs according to the technique employed. SD takes a holistic approach and thus the 
health problem or situation is looked at a more global level and from a greater extent. 
Consequently, this technique is appropriate for facilitating health policy making at the 
macro level.  DES and ABS examine the health problems in more detail (micro level) 
taking into account the properties of individual entities, yet this restricts the extent of the 
system that can be modelled. Therefore usually decisions can be reached with the use of 
DES and ABS only at the operational level. Monte Carlo simulation incorporates the 
random sampling element at aggregated level which makes modelling of population 
based diseases easy to handle. When the individual aspect is important then DES is more 
appropriate. Moreover, DES and SD are more suitable for modelling problems in which 
the time element plays a significant role, such as utilisation of health services’ resources 
and bed/equipment capacity management.  Nonetheless, looking at the categories 
presented in this study, one can see that health risk assessment is pertinent to MCS 
modelling; planning of health services is most of the times handled with DES models 
(and less with SD); and training of health students and managers is prevalent in SD 
approach. Unfortunately, we could not make a distinct category for ABS since the sample 
was so small. Moreover, a year-by-year analysis of the number of papers in each research 
paradigm showed that there are no chronically gaps in the identified categories, and for 
that reason published research in these general fields are continuous. 
 
Relatively few of the published healthcare simulation articles reported significant effects 
that simulation had on the healthcare system being studied. This may imply that although 
authors document the model, the issues they model and the model results, there are few 
real implementation results to report. England and Roberts (1978) implied that the 
reasons behind this are either inadequate models which cannot quantify the impact of the 
human factor or the diversity of authority in healthcare facilities which thwarts the 
simplicity of a single administrative decision to change the system. The latter problem 
lies mostly in the political sphere. However, governmental bodies and other national or 
local council/agency fund a considerable number of studies (43% in our review).   
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In terms of the modelling approach it seems that the use of Commercial, Off-the-Shelf 
(COTS) packages is quite widespread, although many models are still being developed in 
high-level programming languages which usually have larger capabilities in 
accommodating complex behaviours of the system modelled.  Yet, the ease of use that is 
offered by COTS simulation packages allows those who are not computer programmers 
to develop valid simulation models. This gives the opportunity to a number of people 
including some stakeholders of the systems under question to engage in modelling and 
quantify their problems and the impact of alternative actions. However, in this way, 
limitations to the models are posed not only by the data availability and the computer 
operating cost but also by the imagination and capabilities of the modeller and the 
software. Simulation software costs can be high yet since the mid-1990s, a number of low 
cost COTS packages came to market. The later have certainly widened access to 
simulation (Robinson, 2005).  
 
It is widely accepted that one of the most important results of computer simulation in 
healthcare, as well as in other sectors, is the increased understanding of the systems being 
modelled which results from constructing the models. We hope that in the future it will 
become more imperative that healthcare modellers seek close ties and cooperation with 
healthcare administrators to insure utilization and implementation of the worthwhile 
models which are developed. However, the exact same anticipation was expressed some 
30 years ago (England and Roberts, 1978). 
 
As stated by Robinson (2005), simulation techniques have all followed separate paths in 
both research and practice until now. A closer integration among simulation techniques 
conjoined with advances in computing and inclusion of the worldwide web could lead to 
the development of better designed models, with faster execution times, high level of 
graphics and most importantly enhanced user interaction. Such an advance will be in line 
with the requirements of the new, computer literate, generation of users.  
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CONCLUSIONS AND FURTHER REFLECTIONS 
This is a sample review of healthcare simulation studies which aims at identifying 
healthcare problems that are modelled using four popular simulation techniques, namely, 
MCS, DES, SD and ABS. The specific selection criteria of articles which were reviewed 
here may have left out a number of noble publications in the field (e.g. articles that do not 
mention health in their title-topic but refer to health problems with more specific terms 
such as hospitals, patients, etc.; articles which did not appear in journals indexed by ISI 
Web of Knowledge®). The implications of this are that there may be an unintentional 
bias introduced by the specific keywords search and by ISI WoS membership which 
leaves out newer journals that have not yet met the “duration of service” required by the 
ISI WoS and journals which editorial boards do not wish their journal to have an impact 
factor.  These factors may therefore not be taken into account when basing quality on 
impact factors. However, the debate as to whether this is right or wrong is outside the 
scope of this article.  We merely wish to provide an analysis of literature within the scope 
of journals with impact factors and therefore provide some reflection as to the “health” of 
healthcare simulation within a potentially metric-driven world. We hope that this study 
gives an indication of the pulse of research being conducted in the healthcare simulation 
field although generalisation of the results may not hold.  
 
Future research could involve a systematic review of the field including all relevant 
journals from various academic databases and investigate the relationships between 
impact factor and non-impact factor journals. This approach could more accurately map 
the discipline and provide us with statistics of interesting variables similar to the ones 
presented here and with additional ones, such as popular journals, productive institutions 
and frequently published authors. Future research could also broaden the scope of our 
literature review by profiling health related research with the use of other OR/MS 
techniques.  
For the benefit of healthcare and simulation audience, this paper provides an 
overview of research published in various journals from across different subject areas in 
health. This research is likely to help authors, reviewers and editors to better understand 
the potential of different simulation techniques for solving diverse healthcare problems 
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and can also assist upcoming researchers in developing an appreciation of this research 
area and the various issues considered worthy of research and publication. Furthermore, 
we hope that healthcare planners, management engineers, as well as researchers will 
benefit from this study, by having ready access to an up-to-date, indicative collection of 
articles describing these applications. Finally, our study is likely to stimulate researchers 
to explore other research areas by undertaking comparative/cross-journal study.  
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FIGURES 
 
 
Figure 1: The Literature Profiling Methodology 
 
 
Figure 2: Number of papers per simulation techniques over the years 
 
32 
 
TABLES 
Table I: No. of identified and selected papers 
Simulation Methods 
Identified 
papers Percent 
Selected 
papers Percent 
Monte Carlo Simulation 163 64.9% 139 69.15% 
Discrete-Event Simulation 51 20.3% 38 18.91% 
System Dynamics 31 12.4% 17 8.46% 
Agent-Based Simulation 5 2.4% 2 1.00% 
Multiple simulation methods 0 0.0% 5 2.49% 
SUM 251 100.0% 201 100.00% 
 
Table II: Categories and number of papers in healthcare simulation per simulation technique  
MCS 142 
(a) Health risk assessment  
60 (drug development-dose response, air-water-food-soil contamination) 
(b) Prognostic and transmission models of health interventions 
18 (disease transmission stages, regression and robustness models)  
(c) Cost-benefit analysis and policy evaluation of medical treatment and disease management 
(population-based screen-and-treat strategy) 41 
(d) Miscellaneous (literature reviews and taxonomies, health surveys and service delivery) 23 
DES 40 
(a) Planning of healthcare services  
13 
(Hospitals, A&E departments, Scheduling health staff-patient admissions/appointments-
ambulances, bed and equipment capacity, health information systems, organ transplantation, 
locations of healthcare services and facilities design) 
(b) Health economic models  
10 
(cost of providing healthcare, alternative healthcare interventions, screening strategies, cost-
effectiveness of ordering and distribution policies) 
(c) Reviews and  methodology papers (Comparison and evaluation of modelling techniques) 13 
(d) Contagious disease interventions  
4 (Control the spread of diseases/epidemics, plan emergency clinics) 
SD 17 
(a) Public health policy evaluation and economic models  
9 
(Harm reduction policies, treating strategies, long-term health impact, disease population dynamics, 
reconfiguration of health services, health insurance strategies) 
(b) Modelling healthcare systems and infrastructure  
4 
(Unscheduled care, A&E demand pattern, resource deployment, parallel hospital processes, health 
infrastructure disruptions and disasters)  
(c) Training 
3 
(Health policy makers-understanding the dynamics of diseases, students experimentation with 
pharmacological systems) 
(d) Review 1 
ABS 2 
(Interactions of cancer hallmarks and therapies, health data confidentiality)   
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Table III: MCS papers included in the present study 
Sno MC Paper 
1 
Piatt JH, Cosgriff M. Monte Carlo simulation of cerebrospinal fluid shunt failure and definition of instability among shunt-treated 
patients with hydrocephalus. J.Neurosurg. 2007 DEC;107(6):474-478.  
2 
Mannan HR, Knuiman M, Hobbs M. A Markov simulation model for analyzing and forecasting the number of coronary artery 
revascularization procedures in Western Australia. Ann.Epidemiol. 2007 DEC;17(12):964-975.  
3 
Lee D, Shaddick G. Time-varying coefficient models for the analysis of air pollution and health outcome data. Biometrics 2007 
DEC;63(4):1253-1261.  
4 
Fabre MA, Fuseau E, Ficheux H. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected 
after single IV administration in healthy subjects and population PK Modelling. J.Pharm.Sci. 2007 DEC;96(12):3444-3456.  
5 
Antonijevic B, Matthys C, Sioen I, Bilau M, Van Camp J, Willems JL, et al. Simulated impact of a fish based shift in the 
population n-3 fatty acids intake on exposure to dioxins and dioxin-like compounds. Food and Chemical Toxicology 2007 
NOV;45(11):2279-2286.  
6 
Schadlich PK, Schmidt-Lucke C, Huppertz E, Lehmacher W, Nixdorff U, Stellbrink C, et al. Economic evaluation of Enoxaparin 
for anticoagulation in early Cardioversion of persisting nonvalvular atrial fibrillation: A statutory health insurance perspective from 
Germany. American Journal of Cardiovascular Drugs 2007;7(3):199-217.  
7 
Huang ES, Zhang Q, Brown SES, Drum ML, Meltzer DO, Chin MH. The cost-effectiveness of improving diabetes care in US 
Federally qualified community health centers. Health Serv.Res. 2007 DEC;42(6):2174-2193.  
8 
O'Hagan A, Stevenson M, Madan J. Monte Carlo probabilistic sensitivity analysis for patient level simulation models: Efficient 
estimation of mean and variance using ANOVA. Health Econ. 2007 OCT;16(10):1009-1023.  
9 
Schwenkglenks M, Lippuner K. Simulation-based cost-utility analysis of population screening-based alendronate use in 
Switzerland. Osteoporosis Int. 2007 NOV;18(11):1481-1491.  
10 
Djohan D, Yu J, Connell D, Christensen E. Health risk assessment of chlorobenzenes in the air of residential houses using 
probabilistic techniques. Journal of Toxicology and Environmental Health-Part A-Current Issues 2007;70(19):1594-1603.  
11 
Peeler EJ, Murray AG, Thebault A, Brun E, Giovaninni A, Thrush MA. The application of risk analysis in aquatic animal health 
management. Prev.Vet.Med. 2007 SEP 14;81(1-3):3-20.  
12 
Gerkens S, Nechelput M, Annemans L, Peraux B, Mouchart M, Beguin C, et al. A health economic model to assess the cost-
effectiveness of PEG IFN alpha-2a and ribavirin in patients with mild chronic hepatitis C. J.Viral Hepat. 2007 AUG;14(8):523-536.  
13 
Straver JM, Janssen AFW, Linnemann AR, van Boekel MAJS, Beumer RR, Zwietering MH. Number of Salmonella on chicken 
breast filet at retail level and its implications for public health risk. J.Food Prot. 2007 SEP;70(9):2045-2055.  
14 
Vinks AA, van Rossem RN, Mathot RAA, Heijerman HGM, Mouton JW. Pharmacokinetics of aztreonam in healthy subjects and 
patients with cystic fibrosis and evaluation of dose-exposure relationships using Monte Carlo simulation. Antimicrob.Agents 
Chemother. 2007 SEP;51(9):3049-3055.  
15 
Gerkens S, Nechelput M, Annemans L, Peraux B, Beguin C, Horsmans Y. A health economic model to assess the cost-
effectiveness of pegylated interferon alpha-2a and ribavirin in patients with moderate chronic hepatitis C and persistently normal 
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SUM 102 100,0% 
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                                              Table IX: Monte Carlo Simulation Software 
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Healthcare, BASIC, Stata, Hexalog, Java, C11, SAS 1 2,3% 
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                                            Table X: Discrete Event Simulation Software  
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SD Simulation Software No. of papers Percent 
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